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Introduction: In a previous interim 24-week virological safety analysis of the PROTEST study [1], initiation of Maraviroc (MVC)
plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs) in aviremic subjects based on genotypic tropism testing of proviral HIV-
1 DNA was associated with low rates of virological failure. Here we present the final 48-week analysis of the study.
Methods: PROTEST was a phase 4, prospective, single-arm clinical trial (ID: NCT01378910) carried on in 24 HIV care centres in
Spain. Maraviroc-naı̈ve HIV-1-positive adults with HIV-1 RNA (VL) B50 c/mL on stable ART during the previous 6 months,
requiring an ART change due to toxicity, with no antiretroviral resistance to the ART started, and R5 HIV by proviral DNA
genotypic tropism testing (defined as a G2P FPR10% in a singleton), initiated MVC with 2 NRTIs and were followed for 48
weeks. Virological failure was defined as two consecutive VL50 c/mL. Recent adherence was calculated as: (# pills taken/#
pills prescribed during the previous week)*100.
Results: Tropism results were available from 141/175 (80.6%) subjects screened: 87/141 (60%) were R5 and 74/87 (85%) were
finally included in the study. Their median age was 48 years, 16% were women, 31% were MSM, 36% had CDC category C at
study entry, 62% were HCV and 10% were HBV. Median CD4 counts were 616 cells/mm3 at screening, and median nadir
CD4 counts were 143 cells/mm3. Previous ART included PIs in 46 (62%) subjects, NNRTIs in 27 (36%) and integrase inhibitors
(INIs) in 1 (2%). The main reasons for treatment change were dyslipidemia (42%), gastrointestinal symptoms (22%), and liver
toxicity (15%). MVC was given alongside TDF/FTC in 40 (54%) subjects, ABC/3TC in 30 (40%), AZT/3TC in 2 (3%) and ABC/TDF in 2
(3%). Sixty-two (84%) subjects maintained VLB50 c/mL through week 48, whereas 12 (16%) discontinued treatment: two (3%)
withdrew informed consent, one (1%) had a R50X4 shift in HIV tropism between the screening and baseline visits, one (1%)
was lost to follow-up, one (1%) developed an ART-related adverse event (rash), two (3%) died due to non-study-related causes (1
myocardial infarction at week 0 and 1 lung cancer at week 36), and five (7%) developed protocol-defined virological failure,
although two of them regained VLB50 c/mL with the same MVC regimen (Table 1).
Conclusions: Initiation of MVC plus 2 NRTIs in aviremic subjects based on genotypic tropism testing of proviral HIV-1 DNA is
associated with low rates of virological failure up to one year.
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